Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ACI-7104.056 in Parkinson's disease. The expected timing is based on the latest available company guidance and may change.
VacSYn study. 1/3/24- Completed enrollment of cohort 1 and commenced cohort 2. 11/14/24- Interim data reported. 4/2/25- Reported further interim safety and immunogenicity data. Future updates in 2025. Initiate Part 2 in H2 2025. 4/30/25- Further interim results from Part 1 including PD & biomarker data in Q2 2025. 11/04/25:- Further interim Part 1 VacSYn Ph2 PD data incl PD and biomarkers expected Q4 2025. 12/11/25:- Positive interim VacSYn Ph2 PD data reported. Final Part 1 data expected in Mid-2026. 03/05/26:- VacSYn Ph2 interim results to be presented at AD/PD 2026 on March 18, 2026. 03/13/26:- Positive Part 1 VacSYn Ph2 interim data suggest slowed PD progression and 100% immunogenicity; final data mid-2026. 04/30/26:- Updated VacSYn Ph2 interim AD/PD 2026 data; final Part 1 week 104 results expected H2 2026. 08/05/26:- VacSYn Part 1 week 104 data expected H2 2026; $4M grant awarded. 08/11/26:- FDA Fast Track and IND clearance. VacSYn Part 1 week-100 results expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.